Back to top
more

Quipt Home Medical (QIPT)

(Delayed Data from NSDQ)

$2.25 USD

2.25
175,454

-0.02 (-0.88%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $2.26 +0.01 (0.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Green Thumb Industries Inc. (GTBIF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of -125.00% and +4.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

BioLife Solutions, Inc. (BLFS) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 233.33% and 5.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -800% and 6.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -500% and 1.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Canopy Growth (CGC) delivered earnings and revenue surprises of -19.35% and 6.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) Misses Q1 Earnings Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of -0.97% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Quipt Home Medical (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Prestige Consumer Healthcare (PBH) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -10.53% and 3.46%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Phibro (PAHC) Moves 31.8% Higher: Will This Strength Last?

by Zacks Equity Research

Phibro (PAHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 66.67% and 3.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline

by Zacks Equity Research

Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Wall Street Analysts See a 100% Upside in Quipt Home Medical Corp. (QIPT): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 100% upside potential for Quipt Home Medical Corp. (QIPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -250% and 1.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Asensus Surgical (ASXC) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Asensus Surgical (ASXC) delivered earnings and revenue surprises of -28.57% and 18.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Envista (NVST) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Envista (NVST) delivered earnings and revenue surprises of -7.32% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Beats Q4 Earnings Estimates

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 25% and 1.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Reports Break-Even Earnings for Q3

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -100% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strength Seen in Quanterix Corporation (QTRX): Can Its 5.1% Jump Turn into More Strength?

by Zacks Equity Research

Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

Quipt Home Medical Corp. (QIPT) Tops Q2 Earnings Estimates

by Zacks Equity Research

Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 366.67% and 4.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?